Substrate binding stoichiometry and kinetics of the norepinephrine transporter.
The human norepinephrine (NE) transporter (hNET) attenuates neuronal signaling by rapid NE clearance from the synaptic cleft, and NET is a target for cocaine and amphetamines as well as therapeutics for depression, obsessive-compulsive disorder, and post-traumatic stress disorder. In spite of its central importance in the nervous system, little is known about how NET substrates, such as NE, 1-methyl-4-tetrahydropyridinium (MPP+), or amphetamine, interact with NET at the molecular level. Nor do we understand the mechanisms behind the transport rate. Previously we introduced a fluorescent substrate similar to MPP+, which allowed separate and simultaneous binding and transport measurement (Schwartz, J. W., Blakely, R. D., and DeFelice, L. J. (2003) J. Biol. Chem. 278, 9768-9777). Here we use this substrate, 4-(4-(dimethylamino)styrl)-N-methyl-pyridinium (ASP+), in combination with green fluorescent protein-tagged hNETs to measure substrate-transporter stoichiometry and substrate binding kinetics. Calibrated confocal microscopy and fluorescence correlation spectroscopy reveal that hNETs, which are homomultimers, bind one substrate molecule per transporter subunit. Substrate residence at the transporter, obtained from rapid on-off kinetics revealed in fluorescence correlation spectroscopy, is 526 micros. Substrate residence obtained by infinite dilution is 1000 times slower. This novel examination of substrate-transporter kinetics indicates that a single ASP+ molecule binds and unbinds thousands of times before being transported or ultimately dissociated from hNET. Calibrated fluorescent images combined with mass spectroscopy give a transport rate of 0.06 ASP+/hNET-protein/s, thus 36,000 on-off binding events (and 36 actual departures) occur for one transport event. Therefore binding has a low probability of resulting in transport. We interpret these data to mean that inefficient binding could contribute to slow transport rates.
Schwartz
Joel W
JW
Center for Molecular Neuroscience, Vanderbilt University Medical Center, Nashville, Tennessee 37232-8548, USA.
Novarino
Gaia
G
Piston
David W
DW
DeFelice
Louis J
LJ
D015655:1-Methyl-4-phenylpyridinium / Q000031:analogs & derivatives* / Q000494:pharmacology; D000661:Amphetamine / Q000494:pharmacology; D001692:Biological Transport; D002138:Calibration; D002460:Cell Line; D002462:Cell Membrane / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005456:Fluorescent Dyes / Q000494:pharmacology; D049452:Green Fluorescent Proteins / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D013058:Mass Spectrometry; D018613:Microscopy, Confocal; D015233:Models, Statistical; D009638:Norepinephrine / Q000494:pharmacology; D050484:Norepinephrine Plasma Membrane Transport Proteins; D011485:Protein Binding; D011726:Pyridinium Compounds / Q000494:pharmacology; D013379:Substrate Specificity; D027981:Symporters / Q000737:chemistry*; D013997:Time Factors
C032315:4-(4-dimethylaminostyryl)-1-methylpyridinium; D005456:Fluorescent Dyes; D050484:Norepinephrine Plasma Membrane Transport Proteins; D011726:Pyridinium Compounds; C493227:SLC6A2 protein, human; D027981:Symporters; C075732:1-methyl-4-(2-methylphenyl)pyridinium; D049452:Green Fluorescent Proteins; D000661:Amphetamine; D015655:1-Methyl-4-phenylpyridinium; D009638:Norepinephrine